title: A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
abstract: BACKGROUND
  A post marketing surveillance study was conducted to evaluate safety and efficacy of natalizumab in Swedish multiple sclerosis (MS) patients since its introduction in August 2006 until March 2010.
  
  
  METHODS
  Patients were registered in the web-based Swedish MS-registry at 40 locations and evaluated every 6 months. Adverse events and clinical outcomes were recorded.
  
  
  RESULTS
  One thousand one hundred and fifty-two patients were included (71.4% female) and 149 patients stopped treatment; the main reason was planned pregnancy. Anti-natalizumab antibodies were found in 4.5% (52 patients) of which 1.6% displayed persistent antibodies. Serious adverse events were rare, but included three cases with progressive multifocal leukoencephalopathy (PML). There were seven fatal cases, probably unrelated to the natalizumab treatment. For relapsing-remitting MS patients (n=901), mean Expanded Disability Status Scale (EDSS, -10.7%), Multiple Sclerosis Severity Scale (MSSS, -20.4%), Multiple Sclerosis Impact Scale (MSIS-29, physical -9.9%, psychological -13.3%) and Symbol Digit Modalities Test (SDMT, +10.7%) all showed significant improvements during 24 months of treatment with natalizumab. The Swedish web-based MS quality registry proved to function as a platform for post-marketing MS drug surveillance, providing long-term data regarding drug effects and adverse events beyond clinical trials.
  
  
  CONCLUSIONS
  Our results indicate that natalizumab is generally well tolerated and has sustained efficacy for patients with active MS, though the risk of PML is still an important concern.
authors.affiliation: Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden.
authors.forename: Carolina
authors.initials: C
authors.lastname: Holmén
authors.forename: Fredrik
authors.initials: F
authors.lastname: Piehl
authors.forename: Jan
authors.initials: J
authors.lastname: Hillert
authors.forename: Anna
authors.initials: A
authors.lastname: Fogdell-Hahn
authors.forename: Malin
authors.initials: M
authors.lastname: Lundkvist
authors.forename: Elin
authors.initials: E
authors.lastname: Karlberg
authors.forename: Petra
authors.initials: P
authors.lastname: Nilsson
authors.forename: Charlotte
authors.initials: C
authors.lastname: Dahle
authors.forename: Nils
authors.initials: N
authors.lastname: Feltelius
authors.forename: Anders
authors.initials: A
authors.lastname: Svenningsson
authors.forename: Jan
authors.initials: J
authors.lastname: Lycke
authors.forename: Tomas
authors.initials: T
authors.lastname: Olsson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D000069442:Natalizumab; D009483:Neuropsychological Tests; D011358:Product Surveillance, Postmarketing; D012042:Registries; D012720:Severity of Illness Index; D013548:Sweden / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab